Psoriasis is a long-term inflammatory skin condition characterised by significant genetic predisposition and a dysfunctional immune system1.
Normal skin barrier function maturation is between 28-30 days2. Psoriasis involves an accelerated skin maturation process of 3-6 days, causing abnormal growth and build-up of skin cells, leading to the formation of red, silvery plaques3.
Patients living with psoriasis are frequently categorised into two main groups based on the amount of skin affected by psoriasis and its impact on quality of life:
Hydrogel mometasone furoate formulation delivers a similar anti-inflammatory response to ointment mometasone furoate^,9,10, coupled with the benefit of a hydrophilic 3D woven vehicle allowing the active to penetrate the skin for fast relief 8,11.
Hydrogel mometasone furoate formulation delivers a similar anti-inflammatory response to ointment mometasone furoate^,9,10, coupled with the benefit of a hydrophilic 3D woven vehicle allowing the active to penetrate the skin for fast relief 8,11.
PBS Information: Zatamil Lotion and Zatamil Ointment 15g: Restricted benefits.
Coricosteroid-responsive dermatoses. Zatamil Lotion and Zatamil Oinment 15g: Authority required (Streamlined). Refer to PBS Schedule for full authority information. Zatamil Hydrogel and Zatamil Ointment 45g: These are not listed on the PBS.
Before recommending Zatamil please review the Full Product Information (PI). Full PI is available on request from Ego Pharmaceuticals Pty Ltd and can be accessed at ebs.tga.gov.au.
Zatamil (mometasone furoate) Hydrogel: Short term (up to four continuous weeks) relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as psoriasis and atopic dermatitis. Contraindications: Hypersensitivity to mometasone furoate or to other corticosteroids. Viral infections of the skin, tuberculosis, acne rosacea, perioral dermatitis, fungal skin infections and ulcerative conditions. Precautions: Irritation or sensitisation; infection; infants and children; prolonged or extensive use; occlusion; eye contact; pregnancy (Category B3); lactation. Adverse Reactions: Itching; burning; stinging; skin atrophy; acneiform reactions. Dosage and Administration: Zatamil 0.1% hydrogel: Apply a thin film of Zatamil hydrogel to the affected skin area once daily. Zatamil 0.1% Lotion: Apply a few drops of Zatamil lotion to affected skin areas including scalp sites once daily; massage gently and thoroughly until the medication disappears. Zatamil 0.1% Ointment: Apply a thin film of Zatamil ointment to the affected skin area once daily. All Zatamil products are advised for up to 4 weeks’ continuous treatment. Based on TGA product approved PI dated 14/08/2020.
+ Only hydrogel mometasone product in Australia, according to a search of MIMS, PBS and ARTG. Search term 'mometasone furoate'.
^ A 30-minute application of Zatamil Hydrogel and a 70 minute application of mometasone furoate ointment achieve a similar 24 hour anti-inflammatory response (9,10).
1. Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20(6):1475.
2. Lawton S. Skin 1: The structure and functions of the skin. Nurs. Times. 2019;115(12):30-33. 1
3. Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN, Mule PM. Psoriasis: A comprehensive review. J. Pharm. Biol. Sci. 2011;2(6):857-877.
4. Roller L, Gowan J. Psoriasis. [Internet] AJP. 2022 Janaury [cited 2023 March]. Available from https://ajp.com.au/lessons/psoriasis/
5. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.
6. Bakshi H, Nagpal M, Singh M, Dhingra GA, Aggarwal G. Treatment of psoriasis: A comprehensive review of entire therapies. Curr. Drug Saf. 2020;15(2):82-104
7. Therapeutic guidelines for psoriasis [Internet] 2022 August [cited 2023 march 10]. Available from: https://www.tg.org.au/.
8. Harrison IP, Spada F. Hydrogels for Atopic Dermatitis and Wound Management: A Superior Drug Delivery Vehicle. Pharmaceutics. 2018; 10(2):71.
9. Mometasone furoate ointment bioequivalence study C11–009–LBB (ZPS–456). Data on File, Ego Pharmaceuticals Pty Ltd.
10. Mometasone furoate ointment bioequivalence study C11–009–LBB (ZPS–454). Data on File, Ego Pharmaceuticals Pty Ltd.
11. Kopecek J. Polymer chemistry: swell gels. Nature 2002;417(6887);388-9,391.
12. Zatamil Approved Product Information, 14 August 2020.
13. Spada F, Barnes TM, Grieve KA. Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids.Australas J Dermatol. 2018; 59(3):e168-e174.